Fazal, Z. A. et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies. BMC Rheumatol. https://doi.org/10.1186/s41927-024-00376-9 (2024).

Molander, V. et al. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann. Rheum. Dis. 80, 169–175 (2021).

Article  CAS  PubMed  Google Scholar 

Omair, M. A. et al. Venous thromboembolism in rheumatoid arthritis: the added effect of disease activity to traditional risk factors. Open Access Rheumatol. 14, 2342 (2022).

Google Scholar 

Szekanecz, Z., Buch, M. H. & Charles-Schoeman, C. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat. Rev. Rheumatol. https://doi.org/10.1038/s41584-023-01062-9 (2024).

Goldman, A. et al. Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports. Semin. Arthritis Rheum. 67, 152461 (2024).

Article  CAS  PubMed  Google Scholar 

Taylor, P. C. et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 71, 1042–1055 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mease, P. et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann. Rheum. Dis. 79, 1400–1413 (2020).

Article  CAS  PubMed  Google Scholar 

Molander, V. et al. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann. Rheum. Dis. 82, 189–197 (2023).

Article  CAS  PubMed  Google Scholar 

Pugliesi, A. et al. Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials. Semin. Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2024.152563 (2024).

Zavoriti, A. & Miossec, P. Tofacitinib reduces synovial and vascular inflammation but not the prothrombotic effects of inflammatory cytokines on endothelium. ACR Open Rheumatol. https://doi.org/10.1002/acr2.11790 (2025).